uniQure heads into its May 5 Q1 print carrying a double dose of catalysts — a fresh UK regulatory milestone announced this morning and a stock that fell 7% on Wednesday, extending losses into what has been a pivotal week for the gene therapy company.
The headline news is the MHRA development. uniQure confirmed this morning it has completed a successful pre-submission meeting with the UK regulator and plans to file a Marketing Authorization Application for AMT-130 — its Huntington's disease gene therapy — in Q3 2026. That filing would sidestep the core obstacle in the US, where the FDA has required a traditional sham-controlled trial before approving the drug. The UK route gives AMT-130 a credible path to first approval, and the market's reaction Thursday morning — a bounce in pre-market trading after Wednesday's sharp drop — suggests investors noticed.
Short positioning tells a story of persistent but easing skepticism. SI runs at approximately 21.8% of the free float, firmly elevated, but it has fallen from around 24.7% in late March. The sharpest leg down came in the first two weeks of April, when short interest dropped by roughly 3 percentage points — a notable cover of around 1.4 million shares. Since mid-April, SI has stabilised in the low 21% range with minimal weekly drift. The lending market does not add urgency to that picture. Availability remains abundant, with borrowing costs barely above 0.5% annualised — essentially free to borrow. The ORTEX short score sits at 54.4, and at current levels availability is far from tight, meaning there is no mechanical squeeze pressure building from the borrow side.
Options traders have tilted noticeably more cautious heading into earnings. The put/call ratio is running at 0.24, roughly 1.4 standard deviations above its 20-day mean of 0.18 — its highest reading in the past several weeks. The shift is stark against context: through most of March and early April, PCR ran near its 52-week low of 0.13. It began climbing sharply around April 21, coinciding with the stock's recent weakness. That repositioning toward puts ahead of a May 5 print — when the Q4 2024 results triggered a one-day drop of 42% before partially recovering — reflects genuine caution rather than a knee-jerk hedge.
The Street is deeply split on uniQure, and the analyst picture reflects the whiplash from February's results. Goldman Sachs raised its price target to $10 on April 20 while maintaining a Neutral rating — a modest lift, but still far below where the stock trades at $16.73. The bearish camp points to AMT-130's FDA complications, the lack of revenue-generating products, and uncertainty around CBER leadership. The bull case centres on AMT-130's clinical data, the AMT-191 programme for Fabry disease showing durable enzymatic production, and the Bristol Myers Squibb partnership. Several firms — including Mizuho, RBC Capital, and Wells Fargo — upgraded the stock in early March following the crash, with targets ranging from $35 to $60, but those actions are now nearly two months old and predated the current price level. The mean analyst target of $32.81 implies substantial upside from $16.73, though the Goldman target at $10 serves as a reminder that the consensus is far from uniform.
The earnings history makes the May 5 event genuinely worth watching. The last two prints each saw first-day moves of around -40%, both followed by partial recoveries over the next five sessions. That pattern — violent initial reaction, then stabilisation or bounce — sets the frame for how the market has processed uniQure news events. With the UK MHRA announcement landing the week before results, the Q1 print is less about the financial numbers and more about any update on the AMT-130 regulatory strategy, AMT-191 data progression, and how management characterises the path to the UK filing.
See the live data behind this article on ORTEX.
Open QURE on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
